Table 2

Clinical outcomes in the two cohorts of patients with COVID-19 with and without idiopathic pulmonary fibrosis (IPF) before and after propensity score matching

Outcome	IPF group (n=251)	Percentage	Non-IPF group (n=310 809)	Percentage	Risk ratio	95% CI lower	95% CI upper
Before propensity score matching
Mortality within 30 days	40	15.94	5342	1.72	9.27	6.97	12.33
Mortality within 60 days	46	18.33	6087	1.96	9.36	7.20	12.17
Inpatient services	111	44.22	26 929	8.66	5.10	4.44	5.87
Critical care	55	21.91	9120	2.93	7.47	5.91	9.44
Mechanical ventilation	29	11.55	5606	1.80	6.41	4.54	9.03
30-day composite outcome	50	19.92	8740	2.81	7.08	5.52	9.09
60-day composite outcome	54	21.51	9240	2.97	7.24	5.71	9.17
Acute renal failure	65	25.90	11 803	3.80	6.82	5.53	8.41
Need for renal replacement therapy	11	4.38	1311	0.42	10.39	5.82	18.56
Outcome	IPF group (n=251)	Percentage	Non-IPF group (n=251)	Percentage	Risk ratio	95% CI lower	95% CI upper
After propensity score matching
Mortality within 30 days	40	15.94	28	11.16	1.43	0.91	2.24
Mortality within 60 days	46	18.33	30	11.95	1.53	1	2.35
Inpatient services	111	44.22	62	24.70	1.79	1.39	2.32
Critical care	55	21.91	20	7.97	2.75	1.70	4.45
Mechanical ventilation	29	11.55	13	5.18	2.23	1.19	4.19
30-day composite outcome	50	19.92	32	12.75	1.56	1.04	2.35
60-day composite outcome	54	21.51	34	13.55	1.59	1.07	2.35
Acute renal failure	65	25.90	42	16.73	1.55	1.10	2.19